Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 42 entries
Sorted by: Best Match Show Resources per page
Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy.

Journal of immunotherapy (Hagerstown, Md. : 1997)

Berry EC, Mullany S, Quinlivan A, Craig A, New-Tolley J, Slattery J, Sukumaran S, Klebe S, Craig JE, Siggs OM, Wechalekar MD.
PMID: 34570052
J Immunother. 2022 Jan 01;45(1):51-55. doi: 10.1097/CJI.0000000000000394.

Immune checkpoint inhibitor therapy is frequently associated with immune-related adverse events, which occasionally manifest with visual symptoms. Here, we describe a case of unilateral and sudden-onset painless vision loss in an 82-year-old man with metastatic non-small cell lung cancer...

Cite
Berry EC, Mullany S, Quinlivan A, et al. Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy. J Immunother. 2022;45(1):51-55doi: 10.1097/CJI.0000000000000394.
Berry, E. C., Mullany, S., Quinlivan, A., Craig, A., New-Tolley, J., Slattery, J., Sukumaran, S., Klebe, S., Craig, J. E., Siggs, O. M., & Wechalekar, M. D. (2022). Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy. Journal of immunotherapy (Hagerstown, Md. : 1997), 45(1), 51-55. https://doi.org/10.1097/CJI.0000000000000394
Berry, Ella C, et al. "Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy." Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 45,1 (2022): 51-55. doi: https://doi.org/10.1097/CJI.0000000000000394
Berry EC, Mullany S, Quinlivan A, Craig A, New-Tolley J, Slattery J, Sukumaran S, Klebe S, Craig JE, Siggs OM, Wechalekar MD. Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy. J Immunother. 2022 Jan 01;45(1):51-55. doi: 10.1097/CJI.0000000000000394. PMID: 34570052; PMCID: PMC8654273.
Copy Download .nbib Format: NLM
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastritis E, Landau H, Mollee P, Wechalekar A, Palladini G.
PMID: 34783272
Amyloid. 2021 Nov 16;1-7. doi: 10.1080/13506129.2021.2002841. Epub 2021 Nov 16.

AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted...

Cite
Sanchorawala V, Boccadoro M, Gertz M, et al. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2021;1-7doi: 10.1080/13506129.2021.2002841.
Sanchorawala, V., Boccadoro, M., Gertz, M., Hegenbart, U., Kastritis, E., Landau, H., Mollee, P., Wechalekar, A., & Palladini, G. (2021). Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 1-7. https://doi.org/10.1080/13506129.2021.2002841
Sanchorawala, Vaishali, et al. "Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines." Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis vol. (2021): 1-7. doi: https://doi.org/10.1080/13506129.2021.2002841
Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastritis E, Landau H, Mollee P, Wechalekar A, Palladini G. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2021 Nov 16;1-7. doi: 10.1080/13506129.2021.2002841. Epub 2021 Nov 16. PMID: 34783272.
Copy Download .nbib Format: NLM
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Palladini G, Schönland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, Milani P, Ando Y, Westermark P, Dispenzieri A, Merlini G.
PMID: 33410355
Amyloid. 2021 Mar;28(1):1-2. doi: 10.1080/13506129.2020.1868810. Epub 2021 Jan 07.

No abstract available.

Cite
Palladini G, Schönland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28(1):1-2doi: 10.1080/13506129.2020.1868810.
Palladini, G., Schönland, S. O., Sanchorawala, V., Kumar, S., Wechalekar, A., Hegenbart, U., Milani, P., Ando, Y., Westermark, P., Dispenzieri, A., & Merlini, G. (2021). Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 28(1), 1-2. https://doi.org/10.1080/13506129.2020.1868810
Palladini, Giovanni, et al. "Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis." Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis vol. 28,1 (2021): 1-2. doi: https://doi.org/10.1080/13506129.2020.1868810
Palladini G, Schönland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, Milani P, Ando Y, Westermark P, Dispenzieri A, Merlini G. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021 Mar;28(1):1-2. doi: 10.1080/13506129.2020.1868810. Epub 2021 Jan 07. PMID: 33410355.
Copy Download .nbib Format: NLM
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.

British journal of haematology

Chan WY, Howells L, Wilson W, Sanchez E, Ainley L, Chavda SJ, Dowling E, Correia N, Lecat CSY, McMillan A, Wisniowski B, Mahmood S, Papanikolaou X, Lee L, Sive J, Kyriakou C, Wechalekar A, Popat R, Rabin N, Nastouli E, Yong KL, Xu K.
PMID: 34632575
Br J Haematol. 2021 Oct 10; doi: 10.1111/bjh.17864. Epub 2021 Oct 10.

No abstract available.

Cite
Chan WY, Howells L, Wilson W, et al. Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. Br J Haematol. 2021;doi: 10.1111/bjh.17864.
Chan, W. Y., Howells, L., Wilson, W., Sanchez, E., Ainley, L., Chavda, S. J., Dowling, E., Correia, N., Lecat, C. S. Y., McMillan, A., Wisniowski, B., Mahmood, S., Papanikolaou, X., Lee, L., Sive, J., Kyriakou, C., Wechalekar, A., Popat, R., Rabin, N., Nastouli, E., Yong, K. L., & Xu, K. (2021). Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. British journal of haematology, . https://doi.org/10.1111/bjh.17864
Chan, Wei Yee, et al. "Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17864
Chan WY, Howells L, Wilson W, Sanchez E, Ainley L, Chavda SJ, Dowling E, Correia N, Lecat CSY, McMillan A, Wisniowski B, Mahmood S, Papanikolaou X, Lee L, Sive J, Kyriakou C, Wechalekar A, Popat R, Rabin N, Nastouli E, Yong KL, Xu K. Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. Br J Haematol. 2021 Oct 10; doi: 10.1111/bjh.17864. Epub 2021 Oct 10. PMID: 34632575; PMCID: PMC8652995.
Copy Download .nbib Format: NLM
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.

Journal of clinical pharmacology

Luo MM, Zhu PP, Nnane I, Xiong Y, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Weiss BM, Tran N, Qin X, Vermeulen J, Sharma A, Sun YN, Zhou H.
PMID: 34708423
J Clin Pharmacol. 2021 Oct 28; doi: 10.1002/jcph.1994. Epub 2021 Oct 28.

The purpose of this study is to characterize the population pharmacokinetics (popPK) of subcutaneous (SC) daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone and explore the relationship between daratumumab systemic exposure and selected efficacy and safety end points in...

Cite
Luo MM, Zhu PP, Nnane I, et al. Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. J Clin Pharmacol. 2021;doi: 10.1002/jcph.1994.
Luo, M. M., Zhu, P. P., Nnane, I., Xiong, Y., Merlini, G., Comenzo, R. L., Kastritis, E., Wechalekar, A. D., Weiss, B. M., Tran, N., Qin, X., Vermeulen, J., Sharma, A., Sun, Y. N., & Zhou, H. (2021). Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. Journal of clinical pharmacology, . https://doi.org/10.1002/jcph.1994
Luo, Man Melody, et al. "Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis." Journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1002/jcph.1994
Luo MM, Zhu PP, Nnane I, Xiong Y, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Weiss BM, Tran N, Qin X, Vermeulen J, Sharma A, Sun YN, Zhou H. Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. J Clin Pharmacol. 2021 Oct 28; doi: 10.1002/jcph.1994. Epub 2021 Oct 28. PMID: 34708423.
Copy Download .nbib Format: NLM
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.

Blood cancer journal

Ravichandran S, Cohen OC, Law S, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Gillmore JD, Lachmann HJ, Sachchithanantham S, Mahmood S, Hawkins PN, Wechalekar AD.
PMID: 34155191
Blood Cancer J. 2021 Jun 21;11(6):118. doi: 10.1038/s41408-021-00510-7.

The outcomes in systemic AL amyloidosis are dependent on the depth of haematologic response. However, there is limited data on the impact of the speed of response on outcomes. Here we report the impact of speed of response in...

Cite
Ravichandran S, Cohen OC, Law S, et al. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer J. 2021;11(6):118doi: 10.1038/s41408-021-00510-7.
Ravichandran, S., Cohen, O. C., Law, S., Foard, D., Fontana, M., Martinez-Naharro, A., Whelan, C., Gillmore, J. D., Lachmann, H. J., Sachchithanantham, S., Mahmood, S., Hawkins, P. N., & Wechalekar, A. D. (2021). Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood cancer journal, 11(6), 118. https://doi.org/10.1038/s41408-021-00510-7
Ravichandran, Sriram, et al. "Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib." Blood cancer journal vol. 11,6 (2021): 118. doi: https://doi.org/10.1038/s41408-021-00510-7
Ravichandran S, Cohen OC, Law S, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Gillmore JD, Lachmann HJ, Sachchithanantham S, Mahmood S, Hawkins PN, Wechalekar AD. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer J. 2021 Jun 21;11(6):118. doi: 10.1038/s41408-021-00510-7. PMID: 34155191; PMCID: PMC8217489.
Copy Download .nbib Format: NLM
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.

ESC heart failure

Law S, Petrie A, Chacko L, Cohen OC, Ravichandran S, Gilbertson JA, Rowczenio D, Wechalekar A, Martinez-Naharro A, Lachmann HJ, Whelan CJ, Hutt DF, Hawkins PN, Fontana M, Gillmore JD.
PMID: 32924285
ESC Heart Fail. 2020 Sep 13; doi: 10.1002/ehf2.12989. Epub 2020 Sep 13.

AIMS: Cardiac transthyretin amyloidosis (ATTR-CM) is a progressive and fatal condition. Prognosis can be determined at diagnosis according to the National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage. We sought to examine how NAC ATTR stage changes during follow-up...

Cite
Law S, Petrie A, Chacko L, et al. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Fail. 2020;doi: 10.1002/ehf2.12989.
Law, S., Petrie, A., Chacko, L., Cohen, O. C., Ravichandran, S., Gilbertson, J. A., Rowczenio, D., Wechalekar, A., Martinez-Naharro, A., Lachmann, H. J., Whelan, C. J., Hutt, D. F., Hawkins, P. N., Fontana, M., & Gillmore, J. D. (2020). Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC heart failure, . https://doi.org/10.1002/ehf2.12989
Law, Steven, et al. "Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage." ESC heart failure vol. (2020). doi: https://doi.org/10.1002/ehf2.12989
Law S, Petrie A, Chacko L, Cohen OC, Ravichandran S, Gilbertson JA, Rowczenio D, Wechalekar A, Martinez-Naharro A, Lachmann HJ, Whelan CJ, Hutt DF, Hawkins PN, Fontana M, Gillmore JD. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Fail. 2020 Sep 13; doi: 10.1002/ehf2.12989. Epub 2020 Sep 13. PMID: 32924285; PMCID: PMC7755026.
Copy Download .nbib Format: NLM
Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis.

ACR open rheumatology

Brown Z, Metcalf R, Bednarz J, Spargo L, Lee A, Hill C, Wechalekar M, Stavrou C, James M, Cleland L, Proudman S.
PMID: 32453505
ACR Open Rheumatol. 2020 Jun;2(6):371-377. doi: 10.1002/acr2.11132. Epub 2020 May 26.

OBJECTIVE: We aimed to evaluate the associations between response to algorithm-directed treat-to-target conventional synthetic disease-modifying antirheumatic drug therapy and potentially modifiable lifestyle factors, including dietary fish oil supplementation, body mass index (BMI), and smoking history in a rheumatoid arthritis...

Cite
Brown Z, Metcalf R, Bednarz J, et al. Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis. ACR Open Rheumatol. 2020;2(6):371-377doi: 10.1002/acr2.11132.
Brown, Z., Metcalf, R., Bednarz, J., Spargo, L., Lee, A., Hill, C., Wechalekar, M., Stavrou, C., James, M., Cleland, L., & Proudman, S. (2020). Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis. ACR open rheumatology, 2(6), 371-377. https://doi.org/10.1002/acr2.11132
Brown, Zoe, et al. "Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis." ACR open rheumatology vol. 2,6 (2020): 371-377. doi: https://doi.org/10.1002/acr2.11132
Brown Z, Metcalf R, Bednarz J, Spargo L, Lee A, Hill C, Wechalekar M, Stavrou C, James M, Cleland L, Proudman S. Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis. ACR Open Rheumatol. 2020 Jun;2(6):371-377. doi: 10.1002/acr2.11132. Epub 2020 May 26. PMID: 32453505; PMCID: PMC7301874.
Copy Download .nbib Format: NLM
Adding to the Allied Health Student Experience: Motivators, Deterrents, and How to Get More from Peer Teaching.

Journal of allied health

Massy-Westropp N, Snow A, Wechalekar H, Siefken K, Burlakoti A.
PMID: 33646251
J Allied Health. 2021;50(1):61-66.

Volunteering as a peer tutor offers teaching experience to allied health students who will one day teach patients and colleagues. It also provides an opportunity for students to extend themselves personally and academically. Medical and nursing literature supports peer...

Cite
Massy-Westropp N, Snow A, Wechalekar H, et al. Adding to the Allied Health Student Experience: Motivators, Deterrents, and How to Get More from Peer Teaching. J Allied Health. 2021;50(1):61-66
Massy-Westropp, N., Snow, A., Wechalekar, H., Siefken, K., & Burlakoti, A. (2021). Adding to the Allied Health Student Experience: Motivators, Deterrents, and How to Get More from Peer Teaching. Journal of allied health, 50(1), 61-66.
Massy-Westropp, Nicola, et al. "Adding to the Allied Health Student Experience: Motivators, Deterrents, and How to Get More from Peer Teaching." Journal of allied health vol. 50,1 (2021): 61-66.
Massy-Westropp N, Snow A, Wechalekar H, Siefken K, Burlakoti A. Adding to the Allied Health Student Experience: Motivators, Deterrents, and How to Get More from Peer Teaching. J Allied Health. 2021;50(1):61-66. PMID: 33646251.
Copy Download .nbib Format: NLM
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.

Blood cancer journal

Ravichandran S, Cohen OC, Law S, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Gillmore JD, Lachmann HJ, Sachchithanantham S, Mahmood S, Hawkins PN, Wechalekar AD.
PMID: 34155191
Blood Cancer J. 2021 Jun 21;11(6):118. doi: 10.1038/s41408-021-00510-7.

The outcomes in systemic AL amyloidosis are dependent on the depth of haematologic response. However, there is limited data on the impact of the speed of response on outcomes. Here we report the impact of speed of response in...

Cite
Ravichandran S, Cohen OC, Law S, et al. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer J. 2021;11(6):118doi: 10.1038/s41408-021-00510-7.
Ravichandran, S., Cohen, O. C., Law, S., Foard, D., Fontana, M., Martinez-Naharro, A., Whelan, C., Gillmore, J. D., Lachmann, H. J., Sachchithanantham, S., Mahmood, S., Hawkins, P. N., & Wechalekar, A. D. (2021). Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood cancer journal, 11(6), 118. https://doi.org/10.1038/s41408-021-00510-7
Ravichandran, Sriram, et al. "Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib." Blood cancer journal vol. 11,6 (2021): 118. doi: https://doi.org/10.1038/s41408-021-00510-7
Ravichandran S, Cohen OC, Law S, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Gillmore JD, Lachmann HJ, Sachchithanantham S, Mahmood S, Hawkins PN, Wechalekar AD. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer J. 2021 Jun 21;11(6):118. doi: 10.1038/s41408-021-00510-7. PMID: 34155191; PMCID: PMC8217489.
Copy Download .nbib Format: NLM
Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states.

World journal of orthopedics

Wechalekar MD, Smith MD.
PMID: 25405084
World J Orthop. 2014 Nov 18;5(5):566-73. doi: 10.5312/wjo.v5.i5.566. eCollection 2014 Nov 18.

The synovium is the soft tissue lining diarthrodial joints, tendon sheaths and bursae and is composed of intimal and subintimal layers. The intimal layer is composed of type A cells (macrophages) and type B cells (fibroblasts); in health, the...

Cite
Wechalekar MD, Smith MD. Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states. World J Orthop. 2014;5(5):566-73doi: 10.5312/wjo.v5.i5.566.
Wechalekar, M. D., & Smith, M. D. (2014). Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states. World journal of orthopedics, 5(5), 566-73. https://doi.org/10.5312/wjo.v5.i5.566
Wechalekar, Mihir D, and Smith, Malcolm D. "Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states." World journal of orthopedics vol. 5,5 (2014): 566-73. doi: https://doi.org/10.5312/wjo.v5.i5.566
Wechalekar MD, Smith MD. Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states. World J Orthop. 2014 Nov 18;5(5):566-73. doi: 10.5312/wjo.v5.i5.566. eCollection 2014 Nov 18. PMID: 25405084; PMCID: PMC4133463.
Copy Download .nbib Format: NLM
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.

British journal of haematology

Ravichandran S, Cohen OC, Law S, Sachchithanantham S, Mahmood S, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD.
PMID: 34189728
Br J Haematol. 2021 Aug;194(3):587-597. doi: 10.1111/bjh.17636. Epub 2021 Jun 29.

Systemic immunoglobulin light chain amyloidosis (AL) is an incurable disorder, and the natural history is incompletely understood. In this study, we describe its natural history based on an analysis of real-world longitudinal data. All patients seen at the National...

Cite
Ravichandran S, Cohen OC, Law S, et al. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data. Br J Haematol. 2021;194(3):587-597doi: 10.1111/bjh.17636.
Ravichandran, S., Cohen, O. C., Law, S., Sachchithanantham, S., Mahmood, S., Foard, D., Fontana, M., Martinez-Naharro, A., Whelan, C., Gillmore, J. D., Lachmann, H. J., Hawkins, P. N., & Wechalekar, A. D. (2021). Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data. British journal of haematology, 194(3), 587-597. https://doi.org/10.1111/bjh.17636
Ravichandran, Sriram, et al. "Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data." British journal of haematology vol. 194,3 (2021): 587-597. doi: https://doi.org/10.1111/bjh.17636
Ravichandran S, Cohen OC, Law S, Sachchithanantham S, Mahmood S, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data. Br J Haematol. 2021 Aug;194(3):587-597. doi: 10.1111/bjh.17636. Epub 2021 Jun 29. PMID: 34189728.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 42 entries